Eosinophilic oesophagitis: a novel treatment using Montelukast. - Wikidata - awgldk - TriplyDB

Eosinophilic oesophagitis: a novel treatment using Montelukast.

Eosinophilic oesophagitis: a novel treatment using Montelukast.

http://www.wikidata.org/entity/Q35598391

about

Non-surgical interventions for eosinophilic esophagitis Non-surgical interventions for eosinophilic oesophagitis Basic pathogenesis of eosinophilic esophagitis Eosinophilic esophagitis: published evidences for disease subtypes, indications for patient subpopulations, and how to translate patient observations to murine experimental models Eosinophilic esophagitis in adults: An update Recent discoveries and emerging therapeutics in eosinophilic esophagitis An overview of eosinophilic esophagitis Eosinophilic esophagitis Eosinophilic disorders of the gastro-intestinal tract: an update Management of proton pump inhibitor responsive-esophageal eosinophilia and eosinophilic esophagitis: controversies in treatment approaches Proton pump inhibitor-responsive oesophageal eosinophilia and eosinophilic oesophagitis: more similarities than differences Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report.Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics.The link between allergies and eosinophilic esophagitis: implications for management strategies Eosinophilic esophagitis: a newly established cause of dysphagia 52-year-old woman with dysphagia.Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis Advances in clinical management of eosinophilic esophagitis Eosinophilic gastrointestinal diseases: review and update Esophageal granular cell tumor and eosinophilic esophagitis: two interesting entities identified in the same patient Role of mucosal inflammation in eosinophilic esophagitis: review of the literature The physiological and pathophysiological roles of eosinophils in the gastrointestinal tract.Role of acid and nonacid reflux in children with eosinophilic esophagitis compared with patients with gastroesophageal reflux and control patients.The natural course of gastro-oesophageal reflux.Rapidly increasing prevalence of eosinophilic oesophagitis in Western Australia The prevalence and diagnostic utility of endoscopic features of eosinophilic esophagitis: a meta-analysis.Eosinophilic oesophagitis: a clinical update.Tissue remodeling in eosinophilic esophagitis Review article: the pathogenesis and management of eosinophilic oesophagitis.Current hurdles in the management of eosinophilic oesophagitis: the next steps.Effects of leukotriene receptor antagonists on peripheral eosinophil counts and serum IgE levels in children with food allergy.Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review.Elevated levels of leukotriene C4 synthase mRNA distinguish a subpopulation of eosinophilic oesophagitis patients.Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis.Eosinophilic esophagitis: management and pharmacotherapy.Allergy and eosinophil-associated gastrointestinal disorders (EGID).Eosinophilic esophagitis: dilate or medicate? A cost analysis model of the choice of initial therapy Chemotactic factors associated with eosinophilic gastrointestinal diseases.Current evaluation of the dysphagic patient.New efficacy of LTRAs (montelukast sodium): it possibly prevents food-induced abdominal symptoms during oral immunotherapy.

P2860

Q24236562-5272880B-3C55-4B0C-B208-F765D65836F8 Q24246668-1100AAF6-9D0E-4CA8-AD88-670BA1BBADF0 Q24672226-AF4E480E-679E-4D10-AE30-EBAEC1C92C11 Q26741559-7A929101-8E1F-4795-BF65-A30D5BE8ACDD Q26751168-CEE52AEA-8940-4190-82BA-5BE31A3134CE Q26768277-DF6A64AC-8EFD-4E6D-A8C3-79CFB349C78C Q26830656-C473053A-CA40-4A3A-9FB4-E0B1BFBC3668 Q27004593-393BAE67-002D-45AF-BD58-3D3B85F82DBF Q28066026-7A440EEA-178B-4ABF-8930-DEF0A7410F36 Q28080583-6F44D29F-7D38-40E2-8783-19C9FABAA316 Q28082447-EE51DE79-B75F-42BB-B021-DB059371063E Q30234293-A504D109-F673-478D-82D7-B35372BD954F Q33443525-CBD422E6-125C-4643-A5F8-86D759F64F9D Q33649482-F4F54F6E-5710-4F97-AD9D-9EBB94F20A67 Q33868807-7461CFB0-752E-4265-9C44-477ED25D5A5C Q34030937-3D8FB6A1-0435-42D1-BDA3-BA9680E40E34 Q34331377-2BF3746A-0020-42B9-BC4B-48604DD19737 Q34619973-62ADD1E1-92C7-404A-8883-4A0E8FD564F6 Q34640332-3C4229C9-C5B3-44E5-A4DE-1220D4F317AE Q34785160-C5D5D581-41B4-4385-AC8F-D84CDF9EA1CF Q35200699-3F2D3034-5082-459B-B87F-354AC6D0BD9E Q35607573-76D11495-F7FD-4DCE-9C90-D8EAB853AE2F Q35800698-A25DAC3D-F8A7-43A0-BF0B-643D39F3D927 Q35904802-50E7079E-0996-46BC-B83F-A871CE9ED5B0 Q36153520-692CCA50-3AC5-465B-9C44-983DB6D5F20E Q36179681-68BD0495-9D95-4D8B-BAE3-F758D7DC654C Q36185777-E97867ED-E2E8-4F96-8256-FF8BC1502F87 Q36494364-21BB858A-4CCC-4467-9704-058D548CC583 Q36536702-6E25B2F5-68A2-40DC-BD8C-456118075EAD Q36616776-5986ECAC-871B-4870-A35E-5522D5E5CCB1 Q36650141-61FA64CC-DB55-499B-B4A0-1D82CDAF0524 Q36872864-66D946CC-54FA-4EE5-9365-406ED6EBAA7C Q37058183-672D3F9E-03D5-4035-8DEA-1C1512232946 Q37098443-C68B20E1-FB8A-4CA7-847C-1C01BCCA20E0 Q37111841-72EAD4A3-E022-4B09-BC53-19D8CC0850EB Q37249993-16AB60DC-1AA5-4266-B1A0-0403AD50792F Q37297069-B08B1E4D-509F-4F5C-9A2F-EAA4E7D4936A Q37367623-C5F3F6F3-93E2-42D6-A4CE-885C7D95F38F Q37395234-847CF098-7405-4BEA-BF7F-BD0C609BB4B9 Q37523496-C1665EC5-48F1-4F55-97B7-E332B837CD2E

P2860

Eosinophilic oesophagitis: a novel treatment using Montelukast.

http://www.wikidata.org/entity/Q35598391

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Eosinophilic oesophagitis: a novel treatment using Montelukast.

@ast

Eosinophilic oesophagitis: a novel treatment using Montelukast.

@en

type

label

Eosinophilic oesophagitis: a novel treatment using Montelukast.

@ast

Eosinophilic oesophagitis: a novel treatment using Montelukast.

@en

prefLabel

Eosinophilic oesophagitis: a novel treatment using Montelukast.

@ast

Eosinophilic oesophagitis: a novel treatment using Montelukast.

@en

P1433

Q35598391-D42CE8F2-AA6D-47FF-A3DA-52A7328C4319

P1476

Q35598391-0002119C-C0DD-4FC8-A2A2-88C6A13C6CB2

P2093

Q35598391-38761687-38F5-4411-AB71-F2081C4DCD71

Q35598391-B6EB757F-178D-469F-9B61-489F485D1D5C

Q35598391-BCD7D157-D7DB-492C-8658-DF0F26AD7E6A

Q35598391-C8B218A4-2519-4BCF-BAF2-56092A26278B

Q35598391-D611E09F-CCDD-4596-8C0D-FF6C17872942

Q35598391-E7736A31-BEBA-4E3D-99DE-56D905C64B2E

P2860

Q35598391-10623137-304B-496A-96A5-020373FE3078

Q35598391-1614093D-8DAC-4BDD-B45B-B9CFEEFF3A58

Q35598391-4A1DE27C-DBA7-41E3-940E-1B354C916A95

Q35598391-4F2F7C9E-9A73-4519-863D-A1301EFE3ACF

Q35598391-51343E91-BF5A-4FFB-A9BF-7FAD62A96DBA

Q35598391-699FEB39-5529-4F37-94B0-DD0A5024158D

Q35598391-D2838CA0-3458-4B79-9CC8-A941E95C5F0A

Q35598391-F4CD13E2-04C3-450D-9143-762F453AB5F3

Q35598391-F8EFFA5C-9783-4937-B5D9-49215AA99868

P304

Q35598391-96577C55-BAC2-43E5-B45A-1D4C11214EF6

P31

Q35598391-8991A31C-4739-4E67-9DBA-2E041665A139

P356

Q35598391-402D407E-C06A-40D8-B74D-93E452DD7C3C

P407

Q35598391-CDB102E5-3D62-41E3-A7B2-07D9F6A55CC0

P433

Q35598391-CD8E6A2B-3C8A-4C18-AA5B-F958936A4AE5

P478

Q35598391-7D82614A-F18E-439E-9E3C-8DBB45B6EDDF

P577

Q35598391-806277B4-3164-4A4C-B292-4D83218043E4

P698

Q35598391-9AC136D4-4649-4F7B-AE6B-7689D78D97C6

P932

Q35598391-E5C20E93-32AF-46D3-8FAC-5C3078BFFC0C

P356

P1433

P1476

Eosinophilic oesophagitis: a novel treatment using Montelukast.

@en

P2093

C D Morris

http://www.w3.org/2001/XMLSchema#string

C J Lewis

http://www.w3.org/2001/XMLSchema#string

C S Bronder

http://www.w3.org/2001/XMLSchema#string

G R Armstrong

http://www.w3.org/2001/XMLSchema#string

J Whittam

http://www.w3.org/2001/XMLSchema#string

S E A Attwood

http://www.w3.org/2001/XMLSchema#string

P2860

The spectrum of pediatric eosinophilic esophagitis beyond infancy: a clinical series of 30 children.

Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation.

Eosinophilic gastroenteritis with esophageal involvement.

Pharmacology of leukotriene receptor antagonists. More than inhibitors of bronchoconstriction.

The ringed esophagus: histological features of GERD.

Leukotriene modifiers in the treatment of asthma. Look promising across the board of asthma severity.

Use of montelukast as steroid-sparing agent for recurrent eosinophilic gastroenteritis.

Diffuse esophageal leiomyomatosis with localized dense eosinophilic infiltration.

Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group.

P304

181-185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.52.2.181

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12524397

http://www.w3.org/2001/XMLSchema#string

P932

1774975

http://www.w3.org/2001/XMLSchema#string